Current Biomarker Strategies in Autoimmune Neuromuscular Diseases
Cells · 2023
DOI: 10.3390/cells12202456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Menekse Oeztuerk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Neuromuscular Diseases, Guillain-Barre Syndrome, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heinrich Heine University Düsseldorf.
Abstract (Originalsprache)
Inflammatory neuromuscular disorders encompass a diverse group of immune-mediated diseases with varying clinical manifestations and treatment responses. The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosis, predict disease course, and monitor treatment efficacy. However, the rarity and heterogeneity of these disorders pose significant challenges in the identification and implementation of reliable biomarkers. Here, we aim to provide a comprehensive review of biomarkers currently established in Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), and idiopathic inflammatory myopathy (IIM). It highlights the existing biomarkers in these disorders, including diagnostic, prognostic, predictive and monitoring biomarkers, while emphasizing the unmet need for additional specific biomarkers. The limitations and challenges associated with the current biomarkers are discussed, and the potential implications for disease management and personalized treatment strategies are explored. Collectively, biomarkers have the potential to improve the management of inflammatory neuromuscular disorders. However, novel strategies and further research are needed to establish clinically meaningful biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
ORCID-Profile: Tobias Ruck
Förderung
- Heinrich Heine University Düsseldorf
Zitieren
APA
Oeztuerk, M., Henes, A., Schroeter, C. B., Nelke, C., Quint, P., Theissen, L., Meuth, S. G., & Ruck, T. (2023). Current Biomarker Strategies in Autoimmune Neuromuscular Diseases. Cells. https://doi.org/10.3390/cells12202456
Vancouver
Oeztuerk M, Henes A, Schroeter CB, Nelke C, Quint P, Theissen L, et al. Current Biomarker Strategies in Autoimmune Neuromuscular Diseases. Cells. 2023. doi:10.3390/cells12202456
BibTeX
@article{Oeztuerk2023,
author = {Oeztuerk, Menekse and Henes, Antonia and Schroeter, Christina B and Nelke, Christopher and Quint, Paula and Theissen, Lukas and Meuth, Sven G and Ruck, Tobias},
title = {Current Biomarker Strategies in Autoimmune Neuromuscular Diseases},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12202456}
}
EUVIMED